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We undertook a genomewide linkage study in a total of 353 affected sib pairs (ASPs) with schizophrenia. Our
sample consisted of 179 ASPs from the United Kingdom, 134 from Sweden, and 40 from the United States. We
typed 372 microsatellite markers at ∼10-cM intervals. Our strongest finding was a LOD score of 3.87 on chro-
mosome 10q25.3-q26.3, with positive results being contributed by all three samples and a LOD-1 interval of 15
cM. This finding achieved genomewide significance ( ), on the basis of simulation studies. We also foundP ! .05
two regions, 17p11.2-q25.1 (maximum LOD score [MLS]p 3.35) and 22q11 (MLSp 2.29), in which the evidence
for linkage was highly suggestive. Linkage to all of these regions has been supported by other studies. Moreover,
we found strong evidence for linkage (genomewide ) to 17p11.2-q25.1 in a single pedigree with schizophrenia.P ! .02
In our view, the evidence is now sufficiently compelling to undertake detailed mapping studies of these three regions.
Introduction
Schizophrenia (MIM 181500) is a common disorder
with a lifetime morbid risk of 1% (or more, if spectrum
disorders are included) (Gottesman 1991). It is a major
cause of morbidity and consumes a great deal of long-
term medical and social care. Pathophysiological theo-
ries have been dominated for many years by the hy-
pothesis that the disorder reflects a disturbance of
dopaminergic neurotransmission. More recently, this has
been extended to include serotonergic, glutamatergic,
and GABAergic dysfunction (Bray and Owen 2001).
However, strong evidence for a primary neurochemical
abnormality has not been established, and schizophrenia
is increasingly thought of as a neurodevelopmental dis-
order (Weinberger 1987; Murray and Lewis 1988) char-
acterized by abnormal synaptic connectivity (Harrison
1999). A number of risk factors have been implicated
by epidemiological studies (Murray et al. 2003). How-
ever, the direction of causation is often unclear; the find-
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ings rarely suggest particular pathological mechanisms;
and relative risks tend to be small compared with those
conferred by a history of illness in a close relative (Owen
et al. 2002).
A large number of family, twin, and adoption studies
show that individual differences in liability are predom-
inantly genetic, with heritability estimates of ∼80%
(Owen et al. 2002). The most common mode of trans-
mission are probably oligogenic, polygenic, and a mix-
ture of the two with a threshold effect (Owen et al.
2002). However, the number of susceptibility loci, the
disease risk conferred by each locus, the extent of ge-
netic heterogeneity, and the degree of interaction among
loci all remain unknown. Risch (1990) has calculated
that the data for recurrence risks in the relatives of pro-
bands with schizophrenia are incompatible with the ex-
istence of a single locus conferring a relative risk in
siblings (ls) of 13, and, unless extreme epistasis exists,
models with two or three loci of are more plau-ls  2
sible. It should be emphasized that these calculations
are based on the assumption of homogeneity and refer
to populationwide ls. It is quite possible that alleles of
larger effect are operating in some groups of patients—
for example, families chosen for having a high density
of illness. However, such families would also be ex-
pected to occur even under polygenic inheritance, and
their existence does not force the conclusion that alleles
of large effect exist (McGue and Gottesman 1988). As
for other common genetic disorders, the moderate to
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weak effect at any given locus makes the task of iden-
tifying susceptibility genes difficult. It implies the need
for large sample sizes for initial findings and even more
so for replication (Owen et al. 2000). Further difficulties
arise from the fact that the phenotype is mostly syn-
dromic, as well as from the absence of compelling in-
termediate phenotypes that are easy to test in large popu-
lations. Nevertheless, given the evidence for substantial
heritability, the difficulties inherent in studying the brain
directly, and the lack of strong epidemiological clues to
pathophysiology, the case for pursuing the genetics of
schizophrenia is persuasive.
The results of linkage studies of schizophrenia have
seemed to some to be disappointing, with positive stud-
ies often falling short of being compelling and failures
to replicate being abundant. However—as 120 ge-
nomewide studies have been reported and as sample
sizes and, hence, power have increased—positive, rep-
licated linkages to several chromosomal regions have
accumulated. The details of these studies have been
comprehensively reviewed elsewhere (Williams et al.
2002; O’Donovan et al. 2003). Three of the best-sup-
ported regions are 6p24-22 (MIM 600511), 1q21-22
(MIM 604906), and 13q32-34 (MIM 603176). In these
cases, single studies achieved genomewide significance
at (Straub et al. 1995; Blouin et al. 1998; Brzus-P ! .05
towicz et al. 2000), and, in each case, suggestive positive
findings have also been reported in other samples
(Moises et al. 1995; Schizophrenia Linkage Collabo-
rative Group 1996; Maziade et al. 1997; Brzustowicz
et al. 2000; Schwab et al. 2000; Gurling et al. 2001;
Lindholm et al. 2001). Other promising regions in
which positive findings have been obtained from more
than one study include 8p21-22 (MIM 603013), 6q21-
25 (MIM 603175), 22q11-12 (MIM 600850), 5q21-
q33, 10p15-p11, and 1q42 (Williams et al. 2002;
O’Donovan et al. 2003).
None of the above regions has consistently been rep-
licated in the majority of genome scans, and it is likely
that some represent false positives. However, we also
expect true linkages to fail to replicate in complex dis-
orders, because replication of loci with small popula-
tionwide effects requires larger samples than the original
data set (Suarez et al. 1994), and power for replication
is often even less than assumed since initial studies tend
to overestimate effect sizes (Go¨ring et al. 2001). These
issues are likely to be pertinent to schizophrenia, be-
cause the sample sizes for most genome scans have been
small, with typical samples of 20–100 families, while
the largest to date included 294 small pedigrees (DeLisi
et al. 2002). Our previous genome scan (Williams et al.
1999), which was until recently the largest published
study, found no areas of linkage at genomewide signif-
icance and suggested that the genes for schizophrenia
are likely to be of modest to small effect (population-
wide ). It is clear, therefore, that larger studiesls  2
are needed.
Some of the problems of power and replication can
be addressed by meta-analysis, although this has limi-
tations (Levinson et al. 2003). A recent such study in-
cluded 20 schizophrenia genome scans (Lewis et al.
2003). The number of loci meeting aggregate criteria
for significance was much greater than the number of
loci expected by chance ( ), revealing greaterP ! .001
consistency than had been previously recognized. The
authors concluded that schizophrenia loci are highly
likely to be present in some, perhaps even all, of the
regions 2p, 2q, 5q, 3p, 11q, 6p, 1p, 1q, 22q11-12, 8p,
20p, and 14pter-q13. Other regions were also impli-
cated, but the evidence was somewhat weaker. These
were 16p-q, 18q, 10p, 15q, 6q, and 17q. Another meta-
analysis (Badner and Gershon 2002) found significant
results only on chromosomes 8p, 13q, and 22q. The
two studies differed in many important respects, in-
cluding the fundamental approach, but it seems rea-
sonable that because it was based on a larger and more
complete data set, the study by Lewis and colleagues
(2003) identified additional significant regions.
Given that the results of our first sib-pair genome
scan, supported by evidence from genetic epidemiology,
suggested that the genes for common forms of schizo-
phrenia are likely to be of modest to small effect
( ), we undertook a more highly powered genomels  2
scan. We typed markers at 10-cM intervals in a total
of 353 affected sib pairs (ASPs). Our sample consisted
of 179 ASPs from our original U.K. sample, 134 ASPs
from Sweden, and 40 from the United States. It should
be noted that, in our first sib-pair study, we adopted a
two-stage strategy and undertook a genomewide screen
in only 97 of our ASPs (Williams et al. 1999). Moreover,
we only typed a relatively low density of markers (∼20
cM) and did not type parents or unaffected siblings. In
the present study, we typed the ASPs, together with
parents and unaffected siblings, at a greater density (∼10
cM), using the more informative ABI Prism Linkage
Mapping Set, version 2 (Applied Biosystems), as well
as substantially increasing the sample size by including
ASPs from Sweden and the United States. The resulting
sample of 353 ASPs is one of the largest studied to date.
We report linkage of schizophrenia to chromosome
10q25.3-q26.3 (maximum LOD score ),[MLS]p 3.87
with a LOD-1 interval of 15 cM. This finding achieved
genomewide significance ( ), on the basis of sim-P ! .05
ulation studies. We have also identified highly suggestive
evidence for linkage at two other regions, 17p11.2-
q25.1 ( ) and 22q11 ( ). Link-MLSp 3.35 MLSp 2.29
age to all three regions has been supported by other
studies.
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Materials and Methods
Patient Resources
We report data from 353 ASPs (including 353 broad
diagnoses and 287 narrow diagnoses) drawn from 272
families. For narrow diagnosis, both sibs had schizo-
phrenia or schizoaffective disorder, according to the cri-
teria of the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV). The broad category
included extra pairs in which one had a narrow diagnosis
but the other had any nonorganic psychotic disorder or
schizotypal personality disorder. Our sample consisted
of 179 ASPs (170 narrow) from the United Kingdom,
134 ASPs from Sweden (79 narrow), and 40 from the
United States (38 narrow). Within-family relationships
were confirmed by examination of the degree of allele
sharing across the genome, as described below.
Ascertainment and collection of the U.K. sample has
been fully described elsewhere (Williams et al. 1999).
ASPs were ascertained through mental health services
and relatives’ support groups in England, Wales, Scot-
land, and the Republic of Ireland. All individuals were
white and had been born in the United Kingdom or the
Republic of Ireland. All patients gave written, informed
consent, as approved by the Multi-Centre Research
Ethics Committee and the relevant local research ethics
committee. In Sweden, families were ascertained through
the Mental Health Inpatient Register and the Swedish
Second Generation Register. Patients who had a register
diagnosis of “ICD-10 schizophrenia” were included. All
individuals were white and had been born in Sweden.
All gave written, informed consent, as approved by the
institutional review board of the Karolinska Institute. In
Pittsburgh, recruitment occurred primarily at the uni-
versity-affiliated tertiary care center, which also serves
as a catchment-area hospital. Inpatients and outpatients
were also sought at 35 university hospitals, nonacademic
community centers, and hospitals and state facilities lo-
cated within a 500-mile radius of Pittsburgh. All partic-
ipants provided written, informed consent, as approved
by the institutional review board of the University of Pitts-
burgh. All patients were white.
Diagnosis
In the United Kingdom, consensus diagnoses were
made by two independent, trained raters on the basis of
all available clinical information, including a semistruc-
tured interview (PSE-9 [Wing et al. 1974] or SCAN
[Wing et al. 1990]), case notes, and information from
relatives and mental health professionals. All interviews
were conducted by psychiatrists or psychologists. Vi-
gnettes were prepared on background, interview, and
case-note data. Clinical information was collated using
the Operational Criteria Checklist for Psychotic Illness
(OPCRIT) (McGuffin et al. 1991), the Scales for the
Assessment of Positive and Negative Symptoms (SAPS/
SANS), and the Global Assessment Scale (GAS). The
rating scales were completed by the interviewer, and in-
dividual members of pairs were rated by separate raters
in 69.4% of cases. Each case was separately rated by
two independent raters and a consensus diagnosis was
reached. If there were any discrepancies, the case was
brought to a full team meeting so consensus could be
reached or the case was excluded. For each rater to ob-
tain her/his kappa-score reliability, 40 cases were rated
against the consensus diagnosis. Inter-rater reliability for
diagnosis was excellent, with an average kappa score of
0.9 for all raters, for the duration of the study.
The methods used in Sweden were modeled closely
on those used in the United Kingdom. Moreover, the
Swedish raters were trained by members of the U.K.
team. Specially trained research nurses performed a sem-
istructured interview with each patient in her/his home,
using SCAN, SAPS, and SANS. Patients’ lifelong psy-
chiatric records were also collected (average number of
hospitalization records per patient p 10), and, in most
cases, information from the relatives was also obtained.
Vignettes were then prepared by collecting all the data.
Once again, diagnoses were made independently by two
clinicians on the basis of all available information, and
consensus was sought in the case of disagreement. Inter-
rater reliability for diagnosis was established, with an
average kappa score of 10.9. In the United States, clinical
information was obtained using the Diagnostic Interview
for Genetic Studies (DIGS), as well as medical records
and supplemental information from relatives, as appro-
priate (Nurnberger et al. 1994). Consensus diagnoses
were established by two psychiatrists/psychologistsusing
DSM-IV criteria. Those making the diagnoses were blind
to family history. Inter-rater reliability was examined
throughout the study (kappa 10.80). In addition, we
assessed the inter-rater reliability between the U.K. and
U.S. centers by the blind-rating of case histories (kappa
10.90).
Markers
Included in this study were 372 microsatellite markers.
Most ( ) were selected from the ABI Phase Link-np 352
age Mapping Set, version 2, with a further 20 being
added from the Marshfield genetic map (see the Web site
for the Marshfield Center for Medical Genetics). This
resulted in an average intermarker distance of 10.22 cM
across the genome. The marker order and the distances
between them were checked by referring to the high-
resolution genetic map determined by Kong et al. (2002),
where possible, and by using CRI-MAP (Lander and
Green 1987).
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Genotyping
All DNA samples were extracted either from whole
blood or from saline mouthwash samples, using stan-
dard procedures. PCR was performed in 12 ml volumes
containing 24 ng of genomic DNA, 1.4 pmol of each
primer, 400 mM dNTPs, 1.2 ml of 10 # PCR reaction
buffer (Qiagen), and 0.3 U of HotStarTaq polymerase
(Qiagen). All PCRs were performed on MJ Research
Tetrad thermal cyclers, with an initial denaturation stage
at 95C for 15 min, followed by a touchdown procedure
of 11 cycles (5 s at 94C, 5 s at 60C, 10 s at 72C
[0.5C/cycle]), which was then followed by 27 cycles
of 5 s at 94C, 5 s at 54C, and 10 s at 72C, and a
final 10 min at 72C. Reactions for each marker were
prepared separately, with products multiplexed into size-
specific sets prior to gel electrophoresis. All markers were
genotyped on ABI Prism 3100 sequencers using the soft-
ware GeneScan and Genotyper (Applied Biosystems).
Statistical Analysis
Genetic relationships between family members were
confirmed using marker data from across the genome
and a suite of software packages: RELATIVE (Go¨ring
and Ott 1997), RelCheck (Boehnke and Cox 1997; Bro-
man and Weber 1998), and PREST (McPeek and Sun
2000). In-house software and genotypic relative risk
(GRR) (Abecasis et al. 2001) were employed to detect
MZ twins and to ensure that no individual was typed
in two different families. As a result of this extensive
error-checking procedure, 62 individuals were excluded
(half siblings, false paternity, MZ twins, unrelated in-
dividuals). A further 53 individuals were excluded be-
cause of an unacceptably high rate of PCR dropout. A
total of 353 ASPs remained and were included in the
linkage analysis. Non-Mendelian errors were detected
using the software PedCheck (O’Connell and Weeks
1998). In all, 48 markers from the original ABI Phase
Linkage Mapping Set, version 2, were excluded from the
study and replaced on the grounds of having either a
high PCR dropout rate or excessive (112) non-Mende-
lian errors. Data from nine MZ twin pairs who were
genotyped and one individual who was blindly geno-
typed in duplicate allowed us to estimate the genotyp-
ing error rate to be 0.2% (based on 3,033 duplicate
genotypes).
Single-point LOD scores were computed using
SPLINK under the “possible triangle” restrictions (Hol-
mans and Clayton 1995). Multipoint analyses were per-
formed using the MAPMAKER/SIBS package (Kruglyak
and Lander 1995), which calculates the MLS at each
point in the genome by estimating the maximum-like-
lihood–sharing probabilities (identity by descent [IBD])
for each ASP. When parental genotypes are not available,
the degree of inferred allele sharing can be sensitive to
misspecification of marker-allele frequencies, which can
lead to false-positive results. We therefore estimated
marker-allele frequencies by SPLINK directly from our
data set, using maximum-likelihood methods. The anal-
yses and simulations reported were determined for all
possible pairs without weighting, whereby if there were
n affected individuals in one family, they would con-
tribute n(n1)/2 possible ASPs. We also undertook anal-
yses of a single ASP chosen randomly from each family.
With the exception of the linkage peak on chromosome
17, the results were similar to those for all possible pairs
(data not shown).
We obtained empirical significance levels and the ex-
pected number of given LOD scores per genome screen
by simulating replicates of the broad and narrow data
sets under the null hypothesis of no linkage and then
analyzing with MAPMAKER/SIBS. These simulations
maintained the same marker-allele frequencies, marker
locations, family structures, and individuals typed at
each locus as in the observed data set.
The power of the study was estimated by a similar
method. Replicate data sets were simulated, using mark-
ers with four equifrequent alleles every 10 cM. The fam-
ily structures were once again identical to those actually
genotyped. Disease loci were simulated, with a given ls
midway between markers. This was intended to repre-
sent the most unfavorable position for detection of link-
age and therefore to give a conservative estimate of true
power. Power to detect a particular LOD score was es-
timated as the proportion of replicates with at least that
LOD score.
Results
A description of the families from which the 353 ASPs
were drawn is presented in table 1. Simulation studies
of our genome scan under the narrow (broad) diagnostic
criteria suggested that we would have expected to have
obtained, on average, one multipoint MLS of 2.00 (2.06)
per genome scan, while an MLS of 3.82 (3.92) would
have been expected to occur only once in every 20 ge-
nome scans in the absence of linkage. These therefore
correspond to “suggestive” and “significant” thresholds
for genomewide significance, as defined by Lander and
Kruglyak (1995). In genotyping 372 markers spanning
the genome at an average intermarker distance of 10.22
cM, we have extracted, on average, 65.8% of the IBD
information available.
The results of multipoint ASP linkage analysis of all
chromosomes using MAPMAKER/SIBS are presented in
figure 1. Two regions were identified that had a maxi-
mum LOD score of 13.00; these were located on chro-
mosome 10q25.3-q26.3 ( ; all samples, nar-MLSp 3.87
row diagnosis) and on chromosome 17p11.2-q25.1
( ; U.K. samples only, broad diagnosis). TheMLSp 3.35
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Table 1
Summary Description of the Sample Studied
SUBJECT(S)
NO. WITH NARROW DIAGNOSIS (BROAD DIAGNOSIS)
United Kingdom Sweden United States Total
Families 137 97 38 272
Sibling pairs 125 (122) 55 (86) 35 (37) 215 (245)
Sibling trios 10 (14) 3 (9) 1 (1) 14 (24)
Sibling quartets/quintets/sextets 1 (1) 1 (2) 0 (0) 2 (3)
Total no. of ASPs 170 (179) 79 (134) 38 (40) 287 (353)
Families with one parent typed 41 41 0 82
Families with both parents typed 21 38 0 59
Individuals:
Affected offspring 286 (292) 125 (209) 73 (77) 482 (578)
Unaffected offspring typed 43 (37) 143 (81) 4 (0) 190 (118)
linkage on chromosome 10 achieved genomewide sig-
nificance ( ), on the basis of simulation studies,P ! .05
whereas that on chromosome 17 failed to achieve this
stringent criterion and can only be regarded as sugges-
tive. It is interesting that the MLS at 10q consisted of
positive contributions from all three of our combined
sample groups (U.K. , SwedishMLSp 1.44 MLSp
, and U.S. ), whereas the MLS on chro-3.00 MLSp 1.63
mosome 17 was a result of linkage in the U.K. sample
only.
Closer inspection of the data revealed that the linkage
signal on chromosome 17 was, for the most part, the
result of a single pedigree (named C702) containing six
affected siblings, all of whom met our narrow diagnostic
criteria. When family C702 was excluded from our
analysis, the narrow MLS on chromosome 17 dropped
to 0.89 at 68 cM. Multipoint linkage analysis using
MAPMAKER/SIBS of family C702 alone identified a
MLS of 8.32 at 17q (77 cM). Simulations suggested
that a LOD score of 8.32 in family C702 has a ge-
nomewide significance of .Pp .02
We also obtained evidence that was suggestive of link-
age to 22q11 (LOD 2.29 at 4 cM). Notable results were
also obtained on chromosomes 12q24 (LOD 1.43 in the
full sample at 127 cM); 20q12 (LOD 1.54 in the U.K.
sample at 57 cM), using our narrow diagnostic criteria;
and 6q15 (LOD 1.46 in the U.K. sample at 88 cM),
using our broad diagnostic criteria.
Simulations suggested that this study had a power of
10.95 (0.98), 0.61 (0.72), 0.20 (0.24), and 0.03 (0.034)
to detect a susceptibility locus of , 2, 1.5, andlsp 3
1.25, respectively, for the narrow (broad) model with
a genomewide significance of .Pp .05
Discussion
We report here the results of the second-largest ge-
nomewide linkage scan of schizophrenia to date. We
have obtained LOD scores of 13 in two regions, both
of which have received support from other genome
scans. Our strongest finding was a LOD score of 3.87
on chromosome 10q25.3-q26.3 (140–172 cM; 115.8–
135.5 Mb in the UCSC human genome reference se-
quence [April 2003 freeze]), with positive results being
contributed by all three samples and a LOD-1 interval
of 15 cM (155–170 cM; 128.1–135.2 Mb in the UCSC
human genome reference sequence [April 2003 freeze]).
This finding achieved genomewide significance (P !
) according to stringent criteria (Lander and Kruglyak.05
1995), on the basis of simulation studies. The region
identified on chromosome 10 (140–172 cM) is close to
a region that has been implicated in several studies. Lev-
inson et al. (1998) reported a genome scan using 48
pedigrees (126 affected) from Australia and the United
States. One of the most significant findings was at
D10s1239 (130 cM), with a nonparametric linkage
(NPL) score of 2.02 ( ). The positive linkage sig-Pp .01
nal spanned a region defined by D10s677 (117 cM) to
D10s1230 (143 cM). This study was subsequently fol-
lowed up by Mowry et al. (2000), who studied the region
spanning positions 122 cM to 172 cM with a greater
marker density (5 cM) in an extended sample (the orig-
inal pedigrees plus an extra 23 pedigrees [73 affected
individuals]). This was the only region from the original
genome screen for which further supportive evidence for
linkage could be obtained. The analysis identified a peak
defined by D10s1239 (125 cM) to D10s1237 (135 cM)
with the MLS of 2.08 ( ), occurring at D10s168Pp .01
(131 cM). Lerer et al. (2003) recently reported data from
a genome scan of 21 large families (155 affected indi-
viduals) from Israel. They found suggestive evidence for
linkage in a region spanning D10s543 (129 cM) to
D10s587 (148 cM) ( ). Positive findings fromPp .0008
this region have also been reported by Shaw et al. (1998)
and Ewald et al. (2002).
Our second-strongest finding was a LOD score of
3.35 in the U.K. sample on chromosome 17p11.2-q25.1
(44–97 cM; 16.2–72.5 Mb in the UCSC human genome
reference sequence [April 2003 freeze]), with a LOD-1
interval of 17 cM (57–74 cM; 26.6–58.7 Mb in the
Figure 1 The results of multipoint ASP linkage analysis of all chromosomes, performed using MAPMAKER/SIBS. LOD scores (left axis)
are shown for all ASPs ( ) in black, and U.K.-only ASPs in red ( ). Solid and dotted lines refer to narrow and broad diagnosticnp 353 np 179
criteria, respectively. Information content (right axis) at each locus is shown in purple.
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UCSC human genome reference sequence [April 2003
freeze]). This finding fell just short of genomewide sig-
nificance at the level, a value that was set byPp .05
our simulations and thus should be considered as sug-
gestive (Lander and Kruglyak 1995). Much of the link-
age signal at 17q was the result of a single pedigree
(C702) containing six affected siblings, each of whom
met our narrow diagnostic criteria for schizophrenia.
Secondary analysis has allowed us to identify maternal
and paternal haplotypes spanning markers D17S1852
to D17S785 and D17S1857 to D17S949, respectively,
which cosegregate with each affected member of this
family. When family C702 was excluded from analysis,
the narrow MLS at chromosome 17q dropped to 0.89
at 68 cM. However, multipoint linkage analysis using
MAPMAKER/SIBS of family C702 alone identified a
MLS of 8.68 at 17q (77 cM, genomewide ). TheP ! .02
region on chromosome 17 (44–97 cM) overlaps bin
17.3 that showed significant evidence for linkage in the
meta-analysis of Lewis et al. (2003). It is interesting that
this bin had high scores in five of the larger genome
scans from this meta-analysis. It should be noted that
this meta-analysis does not include the data presented
here, but it does include the results of previous geno-
typing of 97 of the U.K. ASPs.
In our genotyping to date, we have extracted 0.67
and 0.63 of the possible IBD information from the
linked regions of chromosomes 10 and 17, respectively,
with the LOD-1 regions spanning 13 cM and 18 cM,
respectively. We are currently aiming to increase the
marker density for both regions in an attempt to reduce
the LOD-1 regions substantially. In parallel to this
purely positional approach, we have also identified sev-
eral candidate genes from the linked regions in which
we are seeking disease-associated variants; these include
SLC6A4 (MIM 182138), CNP1 (MIM 123830), and
ERBB2 (MIM 164870) from chromosome 17 and CAL-
CYON (MIM 604647) and GPR10 (MIM 600895)
from chromosome 10.
We also obtained suggestive evidence for linkage on
chromosomes 22q11 (LOD 2.29 at 4 cM). A linkage
to this region has received support from a number of
studies, and the region is one of only two to have been
implicated in both meta-analyses of schizophrenia ge-
nome scans (Badner and Gershon 2002; Lewis et al.
2003). Our linkage peak also coincides with the re-
gion deleted in velocardiofacial syndrome (VCFS
[MIM 192430]). VCFS, also known as “DiGeorge”
or “Shprintzen” syndrome (MIM 188400), is associated
with small interstitial deletions of chromosome 22q11.
The phenotype of VCFS is variable, but, in addition to
characteristic core features of dysmorphology, abnor-
malities of the palate, and congenital heart disease, there
is strong evidence that individuals with VCFS have a
substantial increase in the risk of psychosis, especially
schizophrenia (Shprintzen et al. 1992; Pulver et al.
1994; Papolos et al. 1996; Murphy et al. 1999). The
largest study (50 adult cases) found that 30% of patients
met diagnostic criteria for psychosis, with 24% meeting
DSM-IV criteria for schizophrenia (Murphy et al.
1999). Clearly, with an estimated prevalence of 1 in
4,000 live births, VCFS cannot be responsible for more
than a small fraction (∼1%) of cases of schizophrenia,
and this estimate is in keeping with empirical data (Ka-
rayiorgou et al. 1995; Ivanov et al. 2003). However,
the markedly increased risk of schizophrenia in VCFS,
together with the linkage findings, suggests that varia-
tion in this region of the genome is of relevance to
schizophrenia more generally.
Recently, two genes in the VCFS region have been
implicated in schizophrenia, PRODH (MIM 606810)
(Liu et al. 2002) and COMT (MIM 116790) (Shifman
et al. 2002). COMT has long been considered a good
candidate gene for schizophrenia because it encodes a
key dopamine catabolic enzyme. There have been sev-
eral studies that have examined a valine-to-methionine
polymorphism that encodes high- and low-activity
forms of COMT, respectively. Prior to the study by
Shifman and colleagues, the evidence for association
between COMT and schizophrenia was weak and not
supported by meta-analysis (Lohmueller et al. 2003),
although the valine allele has been more reliably asso-
ciated with reduced performance in tests of frontal lobe
function (Egan et al. 2001; Malhotra et al. 2002),
providing a possible mechanism by which COMT
might act as a susceptibility or modifying locus for
schizophrenia.
The study by Shifman and colleagues reported highly
statistically significant evidence for association between
COMT and schizophrenia, but this was not attributable
to the Val/Met polymorphism. Instead, the evidence for
association required inclusion of a marker in intron 1
and/or a marker in the 3′ flanking region. We have re-
cently shown that this haplotype is associated with low
COMT expression, a finding that is consistent with the
association between VCFS and schizophrenia and also
the classic hypothesis that schizophrenia results from
excess dopamine (Bray et al. 2003). However, we have
not been able to confirm association between either the
COMT (unpublished data) or the PRODH (Williams
et al. 2003a) haplotypes. Since there are, as yet, no
published replication data, it is premature to conclude
that the reported associations at these loci explain either
the evidence for linkage in this region or the relationship
between VCFS and psychosis. Replication of the specific
COMT findings, in particular, may prove difficult, as
the study of Shifman and colleagues was performed on
a sample of Ashkenazi Jews on the premise that they
are relatively homogeneous for genetic (and environ-
mental) risk factors.
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We also obtained interesting evidence for linkage on
6q15 (LOD 1.46 at 88 cM), 12q24 (LOD 1.43 at 127
cM), and 20q12 (LOD 1.54 at 57 cM). Our signal on
6q is close to the original reports of suggestive linkage
at 100–125 cM on 6q21-23.2 (Cao et al. 1997; Mar-
tinez et al. 1999; Levinson et al. 2000) and is also ad-
jacent to bin 6.4, which showed some evidence for link-
age in the meta-analysis of Lewis et al. (2003). However,
it lies some distance centromeric to the highly significant
findings in Arab-Israeli families (Lerer et al. 2003) and
in extended kindred from northern Sweden (Lindholm
et al. 2001), which were at 140 cM and 180 cM, re-
spectively. Our data, therefore, add further weight to
the view that there may be more than one susceptibility
locus on 6q.
The region giving positive LOD scores on chromo-
some 20 is close to the region of suggestive linkage
reported by Moises and colleagues (1995) in a two-stage
international study and overlaps with bin 20.2, which
gave suggestive evidence for linkage in a recent meta-
analysis (Lewis et al. 2003). There are no previous re-
ports of linkage to 12q24 in schizophrenia. However,
it is notable that the gene encoding the D-amino acid
oxidase (DAAO [MIM 124050]) is located at 118 cM,
9 cM away from the peak in this study. Recently, Chu-
makov and colleagues (2002) reported evidence that
DAO may be a susceptibility locus for schizophrenia,
although, as yet, this finding is unconfirmed in an in-
dependent sample.
Simulation studies suggested that this study had a
power of 10.95 (0.98) to detect a susceptibility locus
of for the narrow (broad) model with a ge-lsp 3
nomewide significance of . However, even withPp .05
353 ASPs, our power to detect effect sizes of ls 2, 1.5,
and 1.25 was only 0.61 (0.72), 0.20 (0.24), and 0.03
(0.034), respectively. This is likely to explain why we
were unable to detect evidence for the relatively well-
established linkages to 6p24-22, 1q21-22, 13q32-34,
and 8p12-22, which were reported elsewhere (see
above). Indeed, we have found association between
schizophrenia and both NRG1 (MIM 142445) on 8p12
and DTNBP1 (MIM 607145) on 6p22.3 in our U.K.
sample, which includes members of the sibships from
the present study (Williams et al. 2003b; Williams et
al., unpublished data). Larger samples—of, say, 600–
800 nuclear families—will be required to detect reliably
the susceptibility genes of moderate-effect size; such
studies may also allow detection of interactions between
loci, relationships between allele sharing at particular
loci, and aspects of the phenotype and loci of smaller
effect.
In conclusion, we present data from one the largest
systematic genomewide linkage studies for schizophre-
nia yet reported. We have found one region, 10q25.3-
q26.3, that satisfies genomewide criteria ( ) forP ! .05
linkage and two that are highly suggestive, 17p11.2-
q25.1 and 22q11. Linkage to all of these regions has
been supported by other studies. Moreover, we found
strong evidence for linkage to 17q in a single pedigree
with schizophrenia. In our view, the evidence is now
sufficiently compelling to undertake detailed mapping
studies of these regions. Indeed, such studies in other
regions, for which there is comparable evidence for link-
age, are beginning to bear fruit, with evidence being
reported for susceptibility genes on 6p (Straub et al.
2002; Schwab et al. 2003), 8p (Stefansson et al. 2002,
2003; Williams et al. 2003b), and 13q (Chumakov et
al. 2002).
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